「screening」の検索結果

Protocol-driven study screening for systematic, scoping and rapid reviews. Turns a proposal or PROSPERO protocol into confirmed eligibility rules, then screens titles/abstracts and full texts with two blinded AI reviewers and a third-reviewer adjudicator: ordered exclusion codes, no silent defaults, resumable batch runs, QC (seed studies, near-miss rechecks, kappa and PABAK), PRISMA 2020 counts, EndNote/Zotero RIS groups, an Excel log, a methods draft and a literature_corpus handoff to academic-paper. Reads RIS, PubMed .nbib, Web of Science and CSV exports; removes duplicates. 8 modes: protocol, quick, pilot, ta-screen, ft-screen, adjudicate, audit, report. Use it to screen records against eligibility criteria, pilot screening, resolve screening conflicts, audit exclusions or report the selection process. Triggers on: screen these papers, title/abstract screening, full-text screening, screening conflicts, inclusion criteria, PRISMA flow, غربالگری مقالات, اسکرینینگ عنوان و چکیده, معیارهای ورود و خروج.

日本語の概要は準備中です。原文の説明を表示しています。

Screening Assistant - AI-PRISMA 6-dimension screening with Groq LLM (100x cheaper) Supports two project types with different confidence thresholds Use when: screening papers, PRISMA screening, inclusion/exclusion criteria Triggers: screen papers, PRISMA screening, inclusion criteria, exclusion criteria, AI screening

日本語の概要は準備中です。原文の説明を表示しています。

Adjudicates whether a hit generated by sanctions, PEP, or adverse-media screening is a true positive, false positive, or requires human escalation. Use whenever a user presents a screening alert, a name match against a watchlist (OFAC SDN, EU consolidated list, UK OFSI, UN list, PEP list, adverse media hit, etc.), or asks to clear a screening hit / reduce false positives / determine whether a flagged name is actually the listed party. Use even when the user describes the task casually — "is this person actually on the sanctions list", "did we get a real match", "clear this alert", "I have a hit on X" — these are all screening-adjudication tasks. Produces a deterministic determination with full audit trail (structured JSON + human-readable narrative). Designed for use by compliance analysts and screening systems.

日本語の概要は準備中です。原文の説明を表示しています。

Generate a spreadsheet of test entries — newly designated names from OFAC, OFSI, and EU sanctions lists plus deliberate variations of those names — to validate that a sanctions screening system catches fresh designations and is tuned to the right fuzziness threshold. Use this whenever the user asks for sanctions list update test data, screening regression test data, screening QA, fuzzy match calibration, or wants to verify their screening lists are current. Trigger even if the user doesn't say 'screening' explicitly — phrases like 'test my sanctions list', 'check our SDN coverage', 'is my list up to date', or 'build me a regression set from the latest designations' should also invoke this skill.

日本語の概要は準備中です。原文の説明を表示しています。

Conducts pre-DPIA threshold screening to determine whether a full Data Protection Impact Assessment is required under GDPR Article 35. Applies the EDPB WP248rev.01 nine-criteria test, national supervisory authority blacklists, and organisational risk appetite to produce a documented screening decision. Keywords: threshold screening, DPIA trigger, pre-DPIA, WP248, Article 35(1), blacklist, screening decision.

日本語の概要は準備中です。原文の説明を表示しています。

Screen and evaluate A-share investment opportunities. Adapts the original deal-screening skill for Chinese market data sources, A-share screening criteria, and domestic deal origination. Triggers on "A股标的筛选", "标的筛选", "screening China", "deal screening A-share", "筛选投资标的", or "screen for [criteria]".

日本語の概要は準備中です。原文の説明を表示しています。

Convert Kanchi-style dividend investing into a repeatable US-stock operating procedure. Use when users ask for かんち式配当投資, dividend screening, dividend growth quality checks, PERxPBR adaptation for US sectors, pullback limit-order planning, or one-page stock memo creation. Covers screening, deep dive, entry planning, and post-purchase monitoring cadence.

Performs structure-based virtual screening using AutoDock Vina, SMINA, GNINA (CNN scoring), and DiffDock-L hybrid workflows with explicit choice rules across rigid vs flexible docking, cross-docking vs self-docking, binding-site detection (P2Rank, fpocket), receptor preparation (PDB2PQR, PROPKA), ligand preparation (meeko, OpenBabel), and ultralarge-library screening (ZINC22, Enamine REAL). Use when screening chemical libraries against a protein target to find candidate binders, ranking docking poses, or selecting a docking workflow for a specific scenario.

日本語の概要は準備中です。原文の説明を表示しています。

Order and interpret lipoprotein(a) [Lp(a)] measurement at least once in a lifetime, apply the risk-enhancer threshold (≥125 nmol/L or ≥50 mg/dL), and run cascade screening of first-degree relatives for premature ASCVD, familial hypercholesterolaemia, or elevated Lp(a) per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 lifetime measurement, how elevated Lp(a) affects LLT initiation and intensification, the cascade screening indications, the interaction of Lp(a) with ASCVD risk estimation, and current therapeutic limitations. Use when a clinician asks when to check Lp(a), how often to repeat Lp(a), elevated Lp(a) what next, treatment for high Lp(a), should I screen my patient's family, Lp(a) and statins, cascade screening indications. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Performs structure-based virtual screening using AutoDock Vina, SMINA, GNINA (CNN scoring), and DiffDock-L hybrid workflows with explicit choice rules across rigid vs flexible docking, cross-docking vs self-docking, binding-site detection (P2Rank, fpocket), receptor preparation (PDB2PQR, PROPKA), ligand preparation (meeko, OpenBabel), and ultralarge-library screening (ZINC22, Enamine REAL). Use when screening chemical libraries against a protein target to find candidate binders, ranking docking poses, or selecting a docking workflow for a specific scenario.

日本語の概要は準備中です。原文の説明を表示しています。

Performs structure-based virtual screening using AutoDock Vina, SMINA, GNINA (CNN scoring), and DiffDock-L hybrid workflows with explicit choice rules across rigid vs flexible docking, cross-docking vs self-docking, binding-site detection (P2Rank, fpocket), receptor preparation (PDB2PQR, PROPKA), ligand preparation (meeko, OpenBabel), and ultralarge-library screening (ZINC22, Enamine REAL). Use when screening chemical libraries against a protein target to find candidate binders, ranking docking poses, or selecting a docking workflow for a specific scenario.

日本語の概要は準備中です。原文の説明を表示しています。

Quickly screen inbound deal flow — CIMs, teasers, and broker materials — against the fund's investment criteria. Extracts key deal metrics, runs a pass/fail framework, and outputs a one-page screening memo. Use when reviewing new deal flow, triaging inbound materials, or deciding whether to take a first call. Triggers on "screen this deal", "review this CIM", "should we look at this", "triage this teaser", or "deal screening".

日本語の概要は準備中です。原文の説明を表示しています。

Use when screening differentially expressed genes from a bulk expression matrix between two user-specified groups, producing DEG tables, a volcano plot, and a clustered heatmap. Triggers include DEG analysis, volcano plot, clustered heatmap, limma-based two-group comparison, and case-vs-control screening. NOT for single-cell RNA-seq, multi-group contrasts, count-model workflows such as DESeq2/edgeR, or non-expression omics data.

日本語の概要は準備中です。原文の説明を表示しています。

Rapid NDA screening with GREEN/YELLOW/RED classification. 10-point checklist for incoming NDAs. Use when triaging NDAs, screening non-disclosure agreements, or routing NDAs for approval.

日本語の概要は準備中です。原文の説明を表示しています。

Guides the Privacy Threshold Analysis screening process to determine whether a full DPIA is required. Provides a quick-screen questionnaire, threshold criteria based on WP248rev.01, escalation triggers, and documentation requirements. Activate when evaluating new processing activities, system changes, or procurement decisions. Keywords: PTA, privacy threshold analysis, DPIA screening, quick-screen, threshold criteria, WP248, escalation triggers.

日本語の概要は準備中です。原文の説明を表示しています。

Manages privacy compliance for employee background checks including criminal record processing under Art. 10 GDPR, DBS checks (UK), national law variations, and reference verification. Applies proportionality and data minimisation to pre-employment screening, defines retention limits, and addresses role-based necessity assessments. Keywords: background check, criminal record, Art. 10, DBS, pre-employment screening, vetting, data minimisation, proportionality.

日本語の概要は準備中です。原文の説明を表示しています。

Find Amazon same-niche competitors by ASIN, with multi-dimensional filtering by click conversion rate, composite conversion rate, click volume, sales volume, reviews, ratings, price, and gross margin to identify potential competitors. Triggered when users mention same-niche competitors, ASIN competitor mining, niche competitor analysis, similar product benchmarking, ASIN benchmarking, niche market competitor list, high-conversion competitor screening, Nexscope product mining, niche competitor by ASIN, ASIN competitor analysis, same niche products, similar products discovery, conversion rate comparison, potential competitor screening, Nexscope ASIN mining. Even if users do not explicitly mention "niche" or "same niche", this skill should be triggered whenever the task involves discovering competitor lists or screening potential competitors based on a specific ASIN within the same market segment.

日本語の概要は準備中です。原文の説明を表示しています。

Determines if PAC/PRA ratio and PAC levels indicate positive or provisionally positive screening for primary aldosteronism. Triggered when a clinician has PAC and PRA results and asks “Is this screening test positive for PA?” or needs to interpret borderline results.

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance on acceptable blood sampling conditions for primary aldosteronism screening when ideal early‑morning supine fasting conditions cannot be met. Triggers include when a clinician says “The patient wasn’t fasting/supine” or questions whether non‑ideal sampling affects screening validity.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends antihypertensive therapy including mineralocorticoid receptor antagonists (MRAs) for patients with a positive primary aldosteronism (PA) screening test who decline confirmatory testing. Triggers include when a patient has positive screening but refuses additional tests and asks "What should I treat with?" or initiates empiric therapy, with preference for MRAs in typical PA presentations (e.g., spontaneous hypokalemia, resistant hypertension, adrenal tumor on CT).

日本語の概要は準備中です。原文の説明を表示しています。

Recommends switching specific anti-hypertensive medications to reduce false-positive and false-negative screening results for primary aldosteronism. Triggered when a clinician notes 'The patient is on ACE inhibitors/ARBs' or suspects medication interference with screening results.

日本語の概要は準備中です。原文の説明を表示しています。

Selects the aldosterone-to-renin ratio (ARR) method over hypokalemia for screening hypertensive patients for primary aldosteronism. Use when a clinician asks what test to use for screening hypertensive patients with resistant hypertension or unexplained hypokalemia for PA.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests periodic screening for autoimmune diseases known to be more prevalent in PAI patients in whom autoimmune origin of PAI has not been excluded; optimal frequency unknown but can be done annually. Use when determining screening schedule for PAI patient with uncertain autoimmune origin.

日本語の概要は準備中です。原文の説明を表示しています。

Reads one export transaction, order or shipment description and returns a DRAFT export review pack: parties to screen with a screening checklist, an item classification worksheet, a red-flag review, licence-determination questions and open items. Use when the user asks to "prepare the export review for this order", "pre-check this shipment for export control", "who do we need to screen on this deal", "build the classification worksheet for this item" or "assemble the trade-compliance file for this technology transfer". Do not use for vendor security or due-diligence screening of a supplier's questionnaire answers; use vendor-risk-screening-brief instead. Never classifies, screens, clears, decides licence need or releases a shipment; trade compliance does. Drafts for human review; never approves, authorises or signs off.

日本語の概要は準備中です。原文の説明を表示しています。